Aerovate Therapeutics, Inc. (AVTE): Price and Financial Metrics

Aerovate Therapeutics, Inc. (AVTE): $12.71

0.34 (+2.75%)

POWR Rating

Component Grades













Add AVTE to Watchlist
Sign Up

Industry: Biotech



in industry

AVTE Stock Price Chart Interactive Chart >

Price chart for AVTE

AVTE Price/Volume Stats

Current price $12.71 52-week high $29.43
Prev. close $12.37 52-week low $7.74
Day low $12.31 Volume 42,600
Day high $13.03 Avg. volume 54,139
50-day MA $14.35 Dividend yield N/A
200-day MA $13.77 Market Cap 310.25M

Aerovate Therapeutics, Inc. (AVTE) Company Bio

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

AVTE Latest News Stream

Event/Time News Detail
Loading, please wait...

AVTE Latest Social Stream

Loading social stream, please wait...

View Full AVTE Social Stream

Latest AVTE News From Around the Web

Below are the latest news stories about Aerovate Therapeutics Inc that investors may wish to consider to help them evaluate AVTE as an investment opportunity.

Wedbush Thinks Aerovate Therapeutics’ Stock is Going to Recover

Wedbush analyst Liana Moussatos reiterated a Buy rating on Aerovate Therapeutics (AVTE – Research Report) today and set a price target of $23.00. The company's shares closed last Friday at $9.46, close to its 52-week low of $9.02. According to, Moussatos is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.0% and a 33.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals. Aerovate Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $26.50.

Catie Powers on TipRanks | December 17, 2021

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, today announced the initiation of its I nhaled I m atinib P ulmonary A rterial H ypertension C linical T rial (IMPAHCT) Phase 2b/Phase 3 trial to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in adult patients with Pulmonary Arterial Hypertension (PAH).

Intrado Digital Media | December 15, 2021

15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital

In this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […]

Yahoo | November 25, 2021

Aerovate Therapeutics (NASDAQ:AVTE) Earns Buy Rating from Wedbush

Wedbush restated their buy rating on shares of Aerovate Therapeutics (NASDAQ:AVTE) in a research report sent to investors on Tuesday, Price reports. They currently have a $22.00 price objective on the stock. A number of other brokerages also recently weighed in on AVTE. Zacks Investment Research raised shares of Aerovate Therapeutics from a sell []

Transcript Daily | November 17, 2021

Aerovate Therapeutics (NASDAQ:AVTE) Posts Earnings Results, Hits Expectations

Aerovate Therapeutics (NASDAQ:AVTE) released its quarterly earnings data on Sunday. The company reported ($0.26) EPS for the quarter, meeting analysts consensus estimates of ($0.26), MarketWatch Earnings reports. NASDAQ AVTE traded down $3.46 during trading hours on Tuesday, hitting $14.00. 6,115 shares of the company traded hands, compared to its average volume of 128,259. The stock []

Dakota Financial News | November 16, 2021

Read More 'AVTE' Stories Here

AVTE Price Returns

1-mo -8.76%
3-mo 33.79%
6-mo -7.50%
1-year N/A
3-year N/A
5-year N/A
YTD 7.80%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6129 seconds.